Private Wealth Management Group LLC Sells 558 Shares of Pfizer Inc. (NYSE:PFE)

Private Wealth Management Group LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 16.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,879 shares of the biopharmaceutical company’s stock after selling 558 shares during the period. Private Wealth Management Group LLC’s holdings in Pfizer were worth $76,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. Long Run Wealth Advisors LLC raised its stake in Pfizer by 12.8% during the fourth quarter. Long Run Wealth Advisors LLC now owns 52,001 shares of the biopharmaceutical company’s stock worth $1,380,000 after buying an additional 5,916 shares during the last quarter. Centennial Wealth Advisory LLC boosted its holdings in shares of Pfizer by 11.3% in the 4th quarter. Centennial Wealth Advisory LLC now owns 24,618 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 2,490 shares during the last quarter. Benchmark Financial Wealth Advisors LLC increased its position in Pfizer by 2.8% in the fourth quarter. Benchmark Financial Wealth Advisors LLC now owns 15,682 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 434 shares during the last quarter. Onyx Bridge Wealth Group LLC lifted its position in shares of Pfizer by 7.4% during the 4th quarter. Onyx Bridge Wealth Group LLC now owns 33,214 shares of the biopharmaceutical company’s stock valued at $881,000 after buying an additional 2,290 shares during the last quarter. Finally, Inman Jager Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $607,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Up 2.3 %

NYSE PFE opened at $26.46 on Thursday. The stock has a market cap of $149.94 billion, a PE ratio of 35.76, a PEG ratio of 0.66 and a beta of 0.64. The company’s 50-day moving average price is $26.27 and its 200-day moving average price is $27.79. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.50%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.